Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.

Published
06 June 2014
From
Merck
AAHIVM, AGS, and ACRIA release updated recommendations for older patients with HIV

The American Academy of HIV Medicine (AAHIVM), ACRIA, and the American Geriatrics Society (AGS) this week announced a major update to its 2011 report, Recommended Treatment Strategies for Clinicians Managing Older Patients with HIV. Revised topics include assessing functional capacity, smoking cessation, and management of diabetes, COPD, osteoporosis, and hypertension.

Published
06 June 2014
From
EATG
Marriage a Barrier to ARV treatment for Swazi Women (part two of a series on Option B+)

This is the second in a three-part series of about women and Option B+ in Africa. "Although Swazi women have better health-seeking behaviour than men, they find it hard to deal with HIV because of socio-cultural barriers, says the study. Many HIV positive married women live in a dilemma between obeying their husbands or following the advice of the health workers."

Published
05 June 2014
From
IPS
Five-drug ART has no advantage over three drugs for early HIV

Starting antiretroviral therapy (ART) with five drugs instead of three offered no virologic or immunologic advantage in people with early HIV infection, according to results of a randomized trial.

Published
04 June 2014
From
International AIDS Society
An activist's guide to TB drugs

TB treatment must be shorter, simpler, less toxic, and more tolerable and affordable. Activists can contribute to the development and uptake of improved TB treatment by calling attention to research, quality of medications, and access priorities.

Published
04 June 2014
From
TAG
‘Appalling service’ provided by Healthcare at Home leaves patients without drugs

Thousands of NHS patients, some seriously ill, have not received vital medicines on time because of problems at the company contracted to deliver the drugs to these patients in their own homes. The failures in the service offered by Healthcare at Home have been described by patient groups as ‘appalling’ and ‘unsafe’, and have left patients with live-threatening conditions frightened about their ability to get hold of their drugs.

Published
03 June 2014
From
Bureau of Investigative Journalism
Study shows prognostic value of viral load monitoring among people living with subtype C HIV in South Africa

Viral load is the single most important predictor of CD4 cell loss among people in South Africa who had not started HIV treatment, investigators report in

Published
02 June 2014
By
Michael Carter
In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

Published
02 June 2014
From
Medscape
Divided Opinions on Feasibility of Kenya’s Option B+ Roll Out

Kenya’s health sector has been facing significant challenges, ranging from a shortage of health care providers to a series of labour strikes. The problems have not only disrupted health services, but have HIV experts divided on whether to roll out Option B+ nationwide or just to pilot it in high volume facilities such as major referral hospitals.

Published
29 May 2014
From
Inter Press Service
No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers.

Published
29 May 2014
From
NATAP

Filter by country